Today: 28 December 2025
Subscribe
Browse Category

Stock Market News 10 November 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company (NYSE: LLY) opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Viasat (VSAT) Soars to a 52‑Week High on Analyst Upgrade; Earnings Beat and ViaSat‑3 F2 Launch Delay in Focus — Nov 10, 2025

Viasat (VSAT) Soars to a 52‑Week High on Analyst Upgrade; Earnings Beat and ViaSat‑3 F2 Launch Delay in Focus — Nov 10, 2025

Viasat, Inc. (NASDAQ: VSAT) rallied to a new 52‑week high on Monday after a fresh Outperform upgrade and $52 price target from Raymond James. The move extends gains from Friday’s Q2 FY2026 results, which showed an adjusted EPS beat and
10 November 2025
 ·  ·  ·  ·  · 
Stocks Today (Nov. 10, 2025): Nvidia Leads Big‑Tech Rebound; Futures Rise as Senate Moves to End Record Shutdown

Stocks Today (Nov. 10, 2025): Nvidia Leads Big‑Tech Rebound; Futures Rise as Senate Moves to End Record Shutdown

Big Tech snapped back to start the week as hopes for a Washington deal brightened the outlook and volatility eased. Here’s what moved markets today—Monday, November 10, 2025. What’s driving the move 1) Washington tailwinds: Senate procedural win Markets reacted
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
VTI & VOO Today (Nov. 10, 2025): Vanguard’s Broad‑Market ETFs Edge Higher on Shutdown Optimism—Latest Moves, Flows, and Why Young Investors Still Favor Them

VTI & VOO Today (Nov. 10, 2025): Vanguard’s Broad‑Market ETFs Edge Higher on Shutdown Optimism—Latest Moves, Flows, and Why Young Investors Still Favor Them

In Monday trading (Nov. 10, 2025), Vanguard’s Total Stock Market ETF (VTI) and S&P 500 ETF (VOO) ticked higher alongside equities as progress toward a U.S. government‑funding deal buoyed sentiment. As of ~15:24 UTC, VTI traded around $333.79 (≈+1.1% on
10 November 2025
 ·  ·  ·  · 
Palantir (PLTR) Jumps as Burry–Karp Spat Heats Up: Fresh Q3 Numbers, Lofty Valuation, and the Bull‑vs‑Bear Case — Nov. 10, 2025

Palantir (PLTR) Jumps as Burry–Karp Spat Heats Up: Fresh Q3 Numbers, Lofty Valuation, and the Bull‑vs‑Bear Case — Nov. 10, 2025

Palantir stock is trading higher today after a bruising post‑earnings pullback last week, even as Wall Street remains sharply divided over the AI contractor’s sky‑high valuation. What’s new today (Nov. 10) Q3 by the numbers: acceleration across the board Palantir’s
10 November 2025
 ·  ·  ·  ·  · 
Vivakor (VIVK) Executes $23M LPG Trade Under $40M Credit Facility — What It Means for Investors Today (Nov. 10, 2025)

Vivakor (VIVK) Executes $23M LPG Trade Under $40M Credit Facility — What It Means for Investors Today (Nov. 10, 2025)

What happened today (Nov. 10, 2025) Vivakor, Inc. (Nasdaq: VIVK) announced that its trading arm, Vivakor Supply & Trading, has kicked off its first LPG transaction—approximately $23 million in contract value—under the company’s $40 million intermediation credit facility. Management framed
10 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS)
10 November 2025
 ·  ·  ·  ·  · 
Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

What Happened Movano Inc. (NASDAQ: MOVE) and Corvex, Inc., a GPU‑accelerated AI cloud company, signed a definitive all‑stock merger agreement. The combined business will focus squarely on secure, high‑performance AI infrastructure—including GPU clusters for training/inference, confidential computing, and inference‑as‑a‑service—repositioning Movano
10 November 2025
 ·  ·  ·  ·  · 
1 … 743 744 745 746 747 … 939
Go toTop